CHAARTCenter for Health Applications of Aerospace Related Technologies
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
CHAART evaluated data from current and planned satellite instruments for mapping, surveillance, prediction, and control of human disease transmission activities, including vector ecology, reservoir and host ecology, and human settlement patterns.
Therefore, in evaluating the existing sensors, CHAART used an approach that allowed individual investigators to identify satellite data appropriate for their own needs.
The list of 16 factors used in the CHAART evaluation includes some that have not yet been quantified because available sensors do not provide adequate spatial, spectral, or temporal resolutions.
One recent CHAART project addressed Lyme disease, a growing concern in the United States.
With the help of CHAART, the investigators correlated those data with landscape features provided by satellite imagery and developed a predictive model of Lyme disease risk for the county Their results have been accepted for publication in the American Journal of Tropical Medicine and Hygiene.
(31,32) A posthoc analysis of ADT plus AAP versus ADT alone assessing outcomes by risk status (per LATITUDE) and disease volume (per CHAARTED) showed a 3-year OS benefit in high-risk (HR 0.54, 95% CI 0.41-0.71, p<0.001) and low-risk (HR 0.66, 95% CI 0.44-0.98, p=0.041), as well as high-volume (HR 0.60, 95% CI, 0.46-0.78, p<0.001) and low-volume (HR 0.64, 95% CI 0.42-0.97, p=0.034) disease.
A pre-specified exploratory subgroup analysis by volume of disease per CHAARTED did, however, show improved OS with the addition of radiotherapy to ADT for patients with low metastatic burden (3-year OS, 81% vs.
Though adverse events were higher with docetaxel in the CHAARTED trial, (10) in the long run, at 12 months from time of treatment, QOL was better in the docetaxel and ADT arm.
Our model assumed all patients begin in the HSPC state, are chemotherapy naive for metastatic disease, eligible to receive ADT and have patient characteristics in line with the CHAARTED trial, which was the most recent trial data available at the time of initiation of this analysis and largest reported group of high-volume patients.
Given the promising early results of the CHAARTED study, the current philosophy towards metastatic PCa treatment may change, as patients may receive chemotherapy prior to the development of castration resistance, which will affect subsequent treatment sequencing.
In contrast to the CHAARTED study, an updated retrospective analysis from the GETUG-AFU 15 trial was presented at GU ASCO in early 2015.
Similar to the CHAARTED results, there was also a notable survival benefit for the subset of patients with metastatic disease.